DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Seddon B. et al.
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial, 2017.
Lancet Oncol 2017;
18: 1397-1410
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.